NVO241018P110000
- 0.05
- -0.03-37.50%
Novo-Nordisk A/S Newsroom
eli lilly and co (LLY.US) shifts investment focus to europe, investing 0.36 billion US dollars in the biotechnology sector in the united kingdom.
The pharmaceutical giant will also study the promotion of anti-obesity drugs in the united kingdom; the Labour government in the united kingdom is trying to attract more foreign investment.
Weight Loss Drugs Have One Big Issue; These Companies Want to Fix It
The good news for the obese population in the USA: FDA is considering allowing the combination version of eli lilly and co (LLY.US) weight loss drug.
(FDA) agreed on Friday to reconsider the decision made last month, which banned private drug compounders from selling their own compounded versions of eli lilly and co's weight loss and diabetes treatment drugs.
Top Gap Ups and Downs on Friday: TSLA, NVO, WFC and More
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Criminal Networks Cash In On Demand For Weight Loss Drugs, Authorities Say
European Equities Traded in the US as American Depositary Receipts Ends Week Higher in Friday Trading
Lilly Expects Zepbound Approval in Japan by Mid-2025: Report
Zealand Pharma is developing a new generation of obesity drug substitutes.
Danish biotechnology company Zealand Pharma is targeting the "next generation" of weight loss drugs. Meanwhile, competitors from various backgrounds are pouring into this weight loss drug market dominated by heavyweight companies novo-nordisk a/s and eli lilly and co. Zealand Pharma CEO Adam Steensberg stated that compared to traditional glp-1 receptor agonist treatment methods, early trials indicate that their experimental weight loss injection has higher weight loss quality - with less muscle loss and fewer side effects. He added that the company is now looking for a global pharmaceutical company to partner with.
Sector Update: Health Care Stocks Edge Higher Pre-Bell Friday
Update: Senator Warren Asks US Antitrust Regulator to 'Carefully Scrutinize' Novo Nordisk's Bid for Catalent
Novo Nordisk to Bolster Leadership Team, Workforce in India
Here's What Dragged Novo Nordisk A/S (NVO) in Q3
Market Chatter: Novo Nordisk Partners With AI Start-ups, Plans to Boost Headcount in India
Is the side effect of GLP-1 drugs too big? Danish pharmaceutical company Zealand advances "next-generation weight loss drugs"
①Although novo-nordisk a/s and eli lilly and co's drugs are effective in weight loss, the side effects they bring should not be ignored. Currently known side effects include significant muscle loss and increased suicidal thoughts; ②Danish pharmaceutical company Zealand states that a weight loss drug they are developing has higher quality in weight loss - less muscle loss and fewer side effects.
U.S. stocks closed: The three major indices are "unconcerned" about the bearish data, Chinese concept stocks rebounded from the downturn.
①Both inflation and unemployment data exceeded expectations, causing a slight decline in the three major U.S. stock indexes; ② The Nasdaq China Golden Dragon Index stabilized and rebounded; ③ AMD released a competitor to Nvidia in the AI chip market, causing a drop in stock price; ④ A weight-loss platform offering a 'budget version GLP-1 medication' saw continuous stock price increase, with analysts warning of risks.
WW Surge After GLP-1 Compounding Announcement Not Justified After Study, Barclay Says
Sector Update: Health Care Stocks Retreat Thursday Afternoon
Novo Holdings to Acquire Majority Stake in Stingray Marine Solutions, a Leading Provider of Aquaculture Technology
Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves